<DOC>
	<DOCNO>NCT02779348</DOCNO>
	<brief_summary>The purpose study determine whether multiple-dose administration nebicapone affect pharmacokinetics warfarin .</brief_summary>
	<brief_title>Effect BIA 3-202 Pharmacokinetics Pharmacodynamics Warfarin</brief_title>
	<detailed_description>Study design methodology : This single-centre , open-label , randomised , two-way crossover study healthy young male female volunteer . The study consist 2 treatment period separate washout period 14 day . In one period , subject receive nebicapone 200 mg thrice-daily ( tid ) 9 day , warfarin 25 mg single-dose concomitantly morning dose nebicapone Day 4 . In period , warfarin 25 mg single-dose administer alone . Warfarin pharmacokinetic pharmacodynamic profile characterise follow warfarin dose .</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Subjects eligible entry study fulfil follow inclusion criterion : Male female subject age 18 45 year , inclusive . Subjects body mass index ( BMI ) 19 30 kg/m2 , inclusive . Healthy determine prestudy medical history , physical examination , vital sign , complete neurological examination 12lead ECG . Clinical laboratory test result clinically acceptable screen admission first treatment period . Negative test HBsAg , antiHCVAb HIV1 HIV2 Ab screen . Negative screen alcohol drug abuse screen admission treatment period . Nonsmokers smoke â‰¤ 10 cigarette equivalent per day . Able willing give write informed consent . ( If female ) She childbearing potential reason surgery , childbearing potential , use one follow method contraception : double barrier , intrauterine device abstinence . ( If female ) She negative urine pregnancy test screen admission treatment period . Subjects eligible entry study fulfil follow exclusion criterion : Clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , haematological , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , endocrine , connective tissue diseases disorder . Clinically relevant surgical history . Personal family history haemostatic disorder . Personal family history bleed complication surgery tooth extraction , nose gingival bleeding , haemorrhagic diathesis . Any abnormality coagulation test . Any abnormality liver function test . A history relevant atopy drug hypersensitivity . History alcoholism drug abuse . Consumed 14 unit alcohol week . Significant infection know inflammatory process screen admission treatment period . Acute gastrointestinal symptom ( e.g. , nausea , vomit , diarrhoea , heartburn ) time screen admission treatment period . Had use medicine within 2 week admission first period may affect safety study assessment , investigator 's opinion . Had previously receive BIA 3202 . Had use investigational drug participate clinical trial within 6 month prior screen . Had participate 2 clinical trial within 12 month prior screen . Had donate receive blood blood product within 3 month prior screen . Vegetarians , vegan medical dietary restriction . Can communicate reliably investigator . Unlikely cooperate requirement study . Unwilling unable give write informed consent . ( If female ) She pregnant breastfeeding . ( If female ) She childbearing potential use approve effective contraceptive method ( doublebarrier , intrauterine device abstinence ) use oral contraceptive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Nebicapone</keyword>
	<keyword>Warfarin</keyword>
</DOC>